The pulmonary drugs market has experienced substantial transformation over recent years, fueled by escalating chronic respiratory disease prevalence, innovative drug delivery mechanisms, and revolutionary therapeutic breakthroughs. Major respiratory conditions such as chronic obstructive pulmonary disease (COPD), asthma, pulmonary arterial hypertension (PAH), cystic fibrosis, idiopathic...